Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Lidocaine in COVID-19 ARDS
NCT04979923Phase 1Unknown
- Sponsor
- Sheikh Zayed Medical College
- Start
- Jul 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of lidocaine in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (3 arms), sponsored by Sheikh Zayed Medical College. Primary endpoint: Cough suppression at 5 minutes. Status: unknown.
02
Drugs
lidocaine
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04979923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04979923.